Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03599102
Other study ID # Pro00031456
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2016
Est. completion date February 2018

Study information

Verified date May 2021
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

LOVED stands for the Living Organ Video Educated Donors (LOVED) program. It is a culturally tailored program for African Americans to reduce the disparity of low rates of living kidney donation. It is a mobile health delivered platform that does not require transplant center visits, thus increasing the reach of the program compared to center-based program to enhance living kidney donation. The purpose of LOVED is to give education and encouragement to those who need a kidney transplant and teach about the process of living donation to be better educated when approaching others about donating a kidney. The ultimate goal of the program is to increase the number of living kidney donor transplants, especially among African Americans in South Carolina. The program was created to educate those in need of a kidney about the donor process, to dispel myths about living donation, discuss who can be asked to donate and develop and practice skills to start asking others for a living kidney donation. The program is designed to be completed using a tablet computer and is made up of weekly video education clips, resources, short quizzes to reinforce the learning points and weekly video chat sessions with others who need a kidney led by a "navigator" who was once a living donor kidney recipient. The video clips are made up of stories and brief educational messages from transplant center staff, physicians, former donors and recipients. The video chat sessions were designed to solve and address individual issues for those enrolled in the program and to give a sense of community as they continue on their journey to find a kidney. This randomized control trial uses groups of 6-9 participants in each LOVED group that lasts 8-weeks each. A total of 60 participants will be recruited with 30 assigned to LOVED and 30 assigned to a standard care groups. This program is funded by a grant from the National Institute of Health and was developed at the Medical University of South Carolina.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date February 2018
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - 18-65 years old - African American - Legally competent - Able to read and speak in English - Able to use tablet computers (after instruction) - Able to use cell phone - 5 years or less on the kidney waitlist with active status including pre-emptive and ESRD patients on dialysis - 10 years or less on dialysis Exclusion Criteria: - Patients who have currently identified PDs moving through the evaluation stage

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
LOVED Intervention


Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (1)

Lead Sponsor Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Assessment of making autonomous decisions Shared Decision Making Questionnaire (SDM-Q-9), a 6 question 4-item Likert scale (1=strongly agree to 4=strongly disagree) involved decision making between the participant and Loved Navigator. Questions were averaged (range 1-4). Lower scores represent better ability to make decisions. 8 weeks
Other Assessment of feelings of trust Assess if the participant feels distrust of study staff, and medical providers during after the trial. Abbreviated Trust Measure, 3 question, 4-item Likert scale between participant and navigator. Question scores were averaged where higher scores indicated more trust (range 1-4). 8 weeks
Other Assessment of cultural competency Assess feelings of inclusion based on race during study process. Experiences of Discrimination, a 5 question, 4-tem Likert scale. Questions were averaged (range 1-4). Higher sum scores represent higher trust perceptions. 8 weeks
Other Assessment of communication satisfaction Assess feelings of how the communication was administrated during the study. Communication Effectiveness Questionnaire, a 9 question 5-item Likert scale between the participant and the navigator, research staff and renal transplant team. Questions were averaged (range 1-4). Higher sum scores represent higher communication perceptions. 8 weeks
Primary Participant adherence to study protocols Tolerability as defined by % retention to study (% of participants who self-remove from the study) Fidelity as defined by %adherence to chat sessions and completion %of video modules. Assessed at 8 weeks
Primary Change in knowledge about living donation Score measures for self-efficacy, knowledge and attitudes to approach others to be a living donor
-LDKT Knowledge Scale (knowledge) (15 item T/F); each correct response adds 1 point. 0-15 range with higher numbers represent higher knowledge.
Change between 0 and 8 weeks and change between 0 and 6 months
Primary Change in attitudes on living donation LDKT Concerns Scale (i.e., measuring attitudes) (21 T/F with one point for each statement suggestive of more worry); 0-21 range with higher results representing more concerns about LDKT. Change between 0 and 8 weeks and change between 0 and 6 months
Primary Change in self-efficacy to ask others to be a living donor Willingness to Discuss LDKT Scale (i.e., measuring self-efficacy (SE)) (1 item each for family, friends, and strangers7 pt. Likert scale) 1-7 range with higher values representing higher SE to approach others about living donation Change between 0 and 8 weeks and change between 0 and 6 months
Secondary Completing living donor kidney transplantation % who identify potential donors, % elected to be screened and, % completing Living donor kidney transplantation (from clinical records compared between groups) 8 weeks, 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04910867 - APOL1 Genetic Testing Program for Living Donors N/A
Completed NCT02723591 - To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients Phase 4
Completed NCT05945511 - Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
Completed NCT02234349 - Bile Acids and Incretins in Pancreas Kidney Transplant Patients N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Not yet recruiting NCT05934383 - Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension N/A
Withdrawn NCT04936971 - Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response Phase 4
Not yet recruiting NCT04540640 - Oxygenated Machine Preservation in Kidney Transplantation N/A
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Recruiting NCT02908139 - Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients N/A
Terminated NCT02417870 - Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation Phase 1/Phase 2
Completed NCT02560558 - Bela 8 Week Dosing Phase 4
Recruiting NCT02154815 - Pre-emptive Kidney Transplantation Quality of Life N/A
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Enrolling by invitation NCT01905514 - ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients N/A
Completed NCT02147210 - Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1 N/A
Recruiting NCT01699360 - The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients Phase 4
Completed NCT01672957 - ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil) N/A
Completed NCT01655563 - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation Phase 2